Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Teh B. W., Mikulska M., Averbuch D., de la Camara R., Hirsch H. H., AKOVA M., ...More

The Lancet Infectious Diseases, vol.24, no.1, 2024 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.1016/s1473-3099(23)00377-8
  • Journal Name: The Lancet Infectious Diseases
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, CINAHL, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Hacettepe University Affiliated: Yes


Patients can be immunocompromised from a diverse range of disease and treatment factors, including malignancies, autoimmune disorders and their treatments, and organ and stem-cell transplantation. Infections are a leading cause of morbidity and mortality in immunocompromised patients, and the disease treatment landscape is continually evolving. Despite being a critical but preventable and curable adverse event, the reporting of infection events in randomised trials lacks sufficient detail while inconsistency of categorisation and definition of infections in observational and registry studies limits comparability and future pooling of data. A core reporting dataset consisting of category, site, severity, organism, and endpoints was developed as a minimum standard for reporting of infection events in immunocompromised patients across study types. Further additional information is recommended depending on study type. The standardised reporting of infectious events and attributable complications in immunocompromised patients will improve diagnostic, treatment, and prevention approaches and facilitate future research in this patient group.